Research progress of sodium butyrate in metabolic-associated fatty liver disease
10.3760/cma.j.cn501113-20201113-00614
- VernacularTitle:丁酸钠在代谢相关脂肪性肝病中的研究进展
- Author:
Ning ZHANG
1
;
Bo QIN
Author Information
1. 重庆医科大学附属第一医院感染科 400010
- Keywords:
Metabolic fatty liver disease;
Sodium butyrate;
Short-chain fatty acids
- From:
Chinese Journal of Hepatology
2021;29(12):1229-1232
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic-associated fatty liver disease (MAFLD) has become the most common chronic liver disease affecting global public health, and its incidence rate is increasing year by year. The molecular mechanism of its pathogenesis is not yet fully understood, and there is a shortage of effective clinical prevention and treatment methods. Studies have found that sodium butyrate can participate in gene regulation, immune regulation, intestinal barrier function regulation, oxidative stress and other in-vivo physiological activities. Furthermore, it also plays an important role in preventing and alleviating the MAFLD occurrence and development. This article reviews the related studies of sodium butyrate on gene expression regulation, fat metabolism improvement, intestinal flora regulation, and steatohepatitis improvement with MAFLD.
